The TADs VP2 DFDLDMLGD(pBpa)DLDMLGC, Gal4(854-874) CGMFNTTTMDDVYNYL(pBpa) ) TPMFEYENLEDNSKEWTSL(pBpa)DNDIPVTTDDC were synthesized using solid phase peptide synthesis in accordance with standard protocols.
30K centrifugal filter device. The protein concentration was measured using absorbance at 280 nm. The identity and purity of the protein was verified by reducing SDS-PAGE with appropriate molecular weight standards. Cysteine 306 in Med15 was alkylated to prevent it from cleaving the disulfide linker between the TADs and biotin. For this purpose, Med15(1-416) was treated with 10 mM DTT for 1 h. Subsequently 40 mM iodoacetamide (1M in 100 mM NaHCO 3 ) was added and the protein solution was incubated in the dark for 45 min. Excess iodoacetamide and any reducing agent were removed using a PD-10 column (GE Healthcare) preequilibrated with Storage buffer that did not contain any reducing agents.
In vitro cross-linking
For each cross-linking reaction utilized for mass spectrometry analysis, biotinylated TAD was dissolved in minimal DMSO and diluted to a 100 µL volume of 100 mM PBS (pH 7.2) such that the final concentration of DMSO was <10% (final TAD concentration 100-300µM). This solution was mixed with 100 µL Med15 (100-300 µM concentration) and irradiated with a 150W 365 nm UV lamp (BIB-150P, Spectroline) at a distance of 20 cm at 4 °C for 2 h. The irradiated sample was then buffer exchanged with a 1 mL 30K MW cutoff concentrator (Millipore) with 100 mM PBS to remove free TAD (4 x 1mL). This solution was subsequently incubated with 10 µg sequencing grade trypsin (Promega) for 5 h at 37 °C. After digesting the sample, trypsin was inactivated by vortexing and incubating at 65 °C for 10 min. Next the sample was added to 100 µL of neutravidin beads (Pierce) prewashed with 100 mM PBS and incubated for 1 hr at 4 °C with shaking. To remove non-specifically bound tryptic Med15 fragments, the neutravidin beads were washed (6 x 1 mL) with 100 mM PBS (pH 7.2). To elute the biotinylated products the beads were incubated 2x with 100 µL Elution buffer (100 mM PBS, 100 mM DTT) for 1 h at 65 °C. The eluted samples were stored at -80 °C until mass spectrometry analysis was performed. Immediately prior to mass spectrometry analysis, the samples were desalted using a C18 ZIP tips (Millipore) and exchanged to 0.1% formic acid, 70% acetonitrile or 70% methanol solution. A combination of MALDI-TOF/TOF and ESI-FT-ICR mass spectrometry (MS) analysis was performed.
Mass spectrometry analysis
For electrospray ionization (ESI) in both positive and negative mode, samples were analyzed with an actively shielded 7 Tesla quadrupole-Fourier transform ion cyclotron resonance mass spectrometer (APEX-Q, Bruker Daltonics, Billerica, MA). Target analytes in electrospray solution (1:1 CH 3 CN:H 2 O with 0.1% HCOOH for positive ion mode, and 1:1 CH 3 CN: H 2 O with 20 mM NH 4 HCO 3 for negative ion mode) were directly infused into an ESI source (Apollo II, Bruker Daltonics) at a flow rate of 70 µL/h. A counterflow of hot (240 °C) nitrogen gas was applied to assist desolvation of ESI droplets. Multiply protonated ions generated by ESI were externally accumulated in a hexapole and transferred into an infinity ICR cell [3] through a series of high-voltage optics for m/z analysis. For external collision induced dissociation (CID), precursor ions were mass-selectively accumulated in the hexapole collision cell at collision voltages ranging from -18-24 V. Argon was used as collision gas. All data were acquired with XMASS software (version 6.1, Bruker Daltonics) in broadband mode from m/z = 200 to 2000 with 512k data points and summed up to 50 scans. Mass spectra were analyzed with MIDAS software. [4] Due to the possibility of cross-linking hindering access to tryptic cleavage sites in the vicinity of the TAD binding sites, up to five trypsin missed cleavages were considered.
For MALDI analysis (performed at the Michigan Proteome Consortium), 5 µL of alphacyano-4-hydroxycinnaminic acid (5 mg/mL in 50% acetonitrile, 0.1% TFA, 2mM ammonium citrate) were added to the avidin purified crosslinked tryptic peptides. Samples were taken to dryness and resuspended in 5 uL of 50% acetonitrile/0.1% TFA. 0.5 uL of this solution were hand-spotted onto a 192-well MALDI target and allowed to dry under atmosphere. MALDI mass spectra were acquired on an Applied Biosystems 4800 Proteomics Analyzer (TOF/TOF) in reflector positive ion mode. Peptide masses were acquired up to 8000 Da. MS spectra were obtained with 2000 laser (Nd-YAG laser operating at 355 nm and 200 Hz) shots. At least 3 trypsin autolysis peaks were used for internal calibration. MS/MS spectra were also acquired in positive ion mode. Signals in the MS/MS spectra were accumulated based on 6,000 laser shots, or until up to 5 peptide fragment ions were observed to reach a signal to noise ratio of 100. Atmosphere, at a pressure of around 6x10 -7 torr was used as collision gas with a collision energy of 2 keV.
Fluorescence polarization assays
Apparent dissociation constants for fluorescein labeled TADs and Med15(1-416) were determined using fluorescence polarization as previously described. 1 For each experiment, 50 nM TAD was incubated with varying concentrations of Med15(1-416) in 100 mM PBS pH 7.2 and incubated for 10 min in 384 well low volume plate (Corning) before being detected using a TECAN Genios Pro plate reader and the dissociation constant calculated as previously described. [1] β-galactosidase assays Low copy yeast plasmids expressing Gal4(1-100) fused to Gal4(840-881), Gcn4 (105-144) or VP2 under the control of the β-actin promoter were generated using standard molecular biology techniques. [5] Plasmids encoding different fragments of Med15 were generated from Ycplac111 Med15 WT, a low copy plasmid that expresses Med15 under the control of its own promoter. [6] LS41∆Med15 [JPY9::ZZ41, Matα his3Δ200 leu2Δ1 trp1Δ63 ura3-52 lys2Δ385 gal4 URA::pZZ41 Med15::TRP] yeast was co-transformed with the plasmids encoding each Gal4(1-100)+TAD fusion and a portion of Med15. The activity of each construct was monitored using β-galactosidase assays as previously described. [6] Supporting Figure 1 . Localization of TAD binding region on Med15. 10 µM of each biotinylated-pBpa-containing TAD was incubated with 1 µM of a Med15 fragment and irradiated with 365 nm light for 5 min. The samples were analyzed via a western blot using Streptavidin-hrp (top gel) and then subsequently re-probed with an antibody for MBP (bottom gel) to use as a loading control. Supporting Figure 5 . MALDI-TOF (top) and ESI FT-ICR MS (positive ion mode, bottom) analysis of crosslinked products involving Gal4 and Med15. Following photocrosslinking, samples were subjected to proteolysis and purification as described in the experimental section. Here, α represents the activator Gal4, β 1 corresponds to Med15 (74-78), β 2 to Med15 (160-174), and β 3 to Med15 (207-217). 
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Supporting Figure 7. MALDI TOF/TOF MS/MS (top) and ESI FT-ICR MS/MS
(positive ion mode, bottom) analysis of the potential crosslinked product Gal4:Med15(74-78). In MALDI TOF/TOF MS/MS, a limited number of peptide backbone fragments were identified. In addition, cleavage of the C-C bond of the pBpa cross-linker was observed. In positive ion mode ESI FT-ICR MS/MS, significantly more extensive backbone cleavage was observed (* = unidentified peak). Here, α represents Gal4 and β corresponds to Med 15 (74-78). Mass (m/z) 2000 1800 1600 1400 1200 1000 800 600 400 
